Jakarta, INTI - OpenAI has introduced a new AI model called GPT-Rosalind, designed to support life sciences research, including biology and drug discovery, on Sunday, April 19, 2026.
The model is named after Rosalind Franklin, who made significant contributions to the discovery of DNA’s structure.
This technology enables researchers to sort and analyze research data more efficiently, helping accelerate the drug development and approval process, which typically takes 10 to 15 years.
GPT-Rosalind also assists in identifying research targets and generating stronger experimental hypotheses.
The model has been tested across fields such as organic chemistry, protein science, and genetics. Researchers can use it to explore relevant scientific literature and design experimental studies.
Collaboration and Challenges in AI Driven Science
AI-driven scientific research is also being advanced by Google DeepMind through its AlphaFold model, which contributed to the 2024 Nobel Prize in Chemistry.
DeepMind CEO Demis Hassabis stated, “For me, the best use of AI is to improve human health and accelerate scientific discovery.”
In addition, Anthropic has launched Claude for Life Sciences, further expanding AI applications in this field.
OpenAI is collaborating with institutions such as Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific to streamline scientific research workflows.
Amgen Vice President Sean Bruich said, “Our unique collaboration with OpenAI allows us to apply their most advanced capabilities and tools in new and innovative ways that could accelerate how we deliver medicines to patients.”
However, some scientists have raised concerns about the rapid adoption of AI in science, including risks of misuse and challenges related to data representation.
To address these concerns, OpenAI has implemented safety mechanisms to prevent potential misuse, such as the development of biological weapons.
GPT-Rosalind is currently available in a research preview and can be accessed through ChatGPT, Codex, and selected APIs.
Conclusion
The introduction of GPT-Rosalind reflects a growing shift toward AI-powered scientific discovery, where data-driven insights can significantly accelerate research outcomes. While the technology offers immense potential in advancing life sciences and improving human health, its long-term success will depend on responsible implementation, strong safeguards, and continuous collaboration across the global research community.
Read more: Practitioners Encourage the Use of AI in Interpreter Training